Utility of urinary pyridinoline and deoxypyridinoline ratio for diagnosis of osteoarthritis at temporomandibular joint

Tanimoto, Kotaro; Ohno, Shigeru; Imada, M.; Honda, K.; Ohno-Nakahara, M.; Kapila, Sunil; Tanne, Kazuo

doi:10.1111/j.0904-2512.2004.00097.x

Cited by 16 publications

(12 citation statements)

References 32 publications

(33 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Assays on urine samples have shown elevated levels of pyridinoline (Pyr) and deoxypyridinoline (Dpyr) collagen cross-links, which are known markers of bone and cartilage turnover, in patients with osteoarthritis of the TMJ. 87 Additionally, elevated amino acid secretion products were found in the urine of patients with chronic muscle pain TMD. 88 Similarly, preliminary studies using serum have suggested increased estrogen levels 53,89 in TMD patients and increased levels of interleukin-1beta and C-reactive protein in arthritic TMJ diseases.…”

Section: Biomedical Approaches To Diagnose Alleviate or Prevent Joimentioning

confidence: 99%

TMJ Disorders: Future Innovations in Diagnostics and Therapeutics

Wadhwa

Kapila

2008

Journal of Dental Education

216

140

View full text Add to dashboard Cite

Because their etiologies and pathogenesis are poorly understood, temporomandibular joint (TMJ) diseases are difficult to diagnose and manage. All current approaches to treatments of TMJ diseases are largely palliative. Definitive and rational diagnoses or treatments can only be achieved through a comprehensive understanding of the etiologies, predisposing factors, and pathogenesis of TMJ diseases. While much work remains to be done in this field, novel findings in biomedicine and developments in imaging and computer technologies are beginning to provide us with a vision of future innovations in the diagnostics and therapeutics of TMJ disorders. These advances include the identification and use of local or systemic biomarkers to diagnose disease or monitor improvements in therapy; the use of imaging technologies for earlier and more sensitive diagnostics; and the use of biomedicine, biomimetics, and imaging to design and manufacture bioengineered joints. Such advances are likely to help to customize and enhance the quality of care we provide to patients with TMJ disorders.

show abstract

Section: Biomedical Approaches To Diagnose Alleviate or Prevent Joimentioning

confidence: 99%

TMJ Disorders: Future Innovations in Diagnostics and Therapeutics

Wadhwa

Kapila

2008

Journal of Dental Education

216

140

View full text Add to dashboard Cite

show abstract

“…Urinary concentration of PD/DPD ratio was found significantly higher in the OA patients than in the controls. However, the PD/PDP ratio was not associated with any specific clinical or radiological findings [24]. Another bone turnover-resorption-marker CTX-I was assessed in patients with erosive and non-erosive OA of the hands.…”

Section: Resultsmentioning

confidence: 99%

Assessment of Disease Activity and Progression of Osteoarthritis With Using Molecular Markers of Cartilage and Synovium Turnover

Ofluoğlu¹,

Ofluoğlu²

2005

CRR

View full text Add to dashboard Cite

Osteoarthritis (OA) is the most common joint disease, which is characterized by cartilage loss and concomitant alteration of synovium and subchondral bone metabolism. Pain and stiffness in the affected joints are the main complains. It also causes physical functional impairment. The measurement of joint space width by plain radiography is currently established method for assessing the progression of the disease. This method however has some limitations. The most important issue is to determine early OA before significant joint damage has occurred. When there is radiological evidence of OA, significant joint damage has often already occurred. Therefore, there is need for noninvasive methods that can be repeated and have better sensitivity than plain radiography to identify patients at high risk for destructive OA and monitoring drug efficacy.Molecular markers are released into biological fluids during tissue biosynthesis and turnover. They can be measured by immunoassay. Several molecular markers of bone, cartilage and synovium have been described such as crosslinking telopeptide of collagen type II (CTX II), Glc-Gal-PYD, hyaluronic acid, type I collagen.In conclusion, using a newly developed molecular marker, early OA can be properly detected before significant joint destruction has occurred.

show abstract

“…Serum NPIIIP was measured by radioimmunoassay using a commercial procollagen III kit (Orion Diagnostica, Espoo, Finland). PYR and D‐PYR were estimated using high‐performance liquid chromatography (HPLC) as described previously 8…”

Section: Methodsmentioning

confidence: 99%

Clinical Correlations of Potential Activity Markers in Systemic Sclerosis

Bečvář

Štork

Pešáková

et al. 2005

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

The objectives of the project were the following: (1) to establish a group of patients with a confirmed diagnosis of systemic sclerosis (Ssc), (2) to perform a detailed entrance examination of each patient, (3) to determine concentrations of potential activity markers, and (4) to make a comprehensive examination of each patient 1 year after inclusion into the study. A total of 49 patients were examined, 36 with a limited form of SSc, 9 with diffuse SSc, and 4 with other forms of SSc. We determined plasma or serum levels of the N-terminal propeptide of procollagen type III (NPIIIP), interleukin-6 (IL-6), soluble receptor for interleukin-2 (sIL-2r), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular adhesion molecule-1 (sVCAM-1), von Willebrand factor antigen (vWFAg), and big endothelin-1 (BET-1) using commercial kits, and urinary excretion of pyridinoline (PYR) and deoxypyridinoline (D-PYR) using high-performance liquid chromatography. Correlations of these markers with selected clinical data were calculated. The mean levels of all potential activity markers were increased compared with normal values, but differences were not significant. The levels of NPIIIP, D-PYR, and IL-6 were normal. The measured values after 1 year did not differ from the entry values. At entry, NPIIIP concentrations correlated with the finger-to-palm distance, and D-PYR corresponded with findings on a simplified health assessment questionnaire (FQ). IL-6 levels correlated with the leukocyte count, sIL-2r with the FQ, and ET-1 with the diffuse lung capacity for carbon monoxide. In general, we found only a few clinical correlates of potential activity markers. Our data confirmed the correlations of collagen metabolism markers with skin involvement and FQ, as was reported previously. Larger studies in this field are needed.

show abstract

Utility of urinary pyridinoline and deoxypyridinoline ratio for diagnosis of osteoarthritis at temporomandibular joint

Abstract: These findings suggest that the level of Pyr and the Pyr/Dpyr ratio in urine may be a useful diagnostic indicator for intra-articular pathologic changes during TMJ OA.

Cited by 16 publications

References 32 publications

TMJ Disorders: Future Innovations in Diagnostics and Therapeutics

TMJ Disorders: Future Innovations in Diagnostics and Therapeutics

Assessment of Disease Activity and Progression of Osteoarthritis With Using Molecular Markers of Cartilage and Synovium Turnover

Clinical Correlations of Potential Activity Markers in Systemic Sclerosis

Contact Info

Product

Resources

About